CY1115685T1 - Φαρμακευτικη συνθεση προς αγωγη εναντι αϋπνιας μεσω υπογλωσσιας χορηγησης - Google Patents
Φαρμακευτικη συνθεση προς αγωγη εναντι αϋπνιας μεσω υπογλωσσιας χορηγησηςInfo
- Publication number
- CY1115685T1 CY1115685T1 CY20141100588T CY141100588T CY1115685T1 CY 1115685 T1 CY1115685 T1 CY 1115685T1 CY 20141100588 T CY20141100588 T CY 20141100588T CY 141100588 T CY141100588 T CY 141100588T CY 1115685 T1 CY1115685 T1 CY 1115685T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical composition
- composition
- insomnia
- composition against
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 3
- 206010022437 insomnia Diseases 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 230000035587 bioadhesion Effects 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
Abstract
Περιγράφεται φαρμακευτική σύνθεση προς αγωγή έναντι αϋπνίας. Η σύνθεση περιλαμβάνει ουσιαστικά ελεύθερο ύδατος, διατεταγμένο μείγμα τουλάχιστον ενός φαρμακευτικώς δραστικού παράγοντα χρήσιμου στην αγωγή έναντι αϋπνίας υπό τη μορφή μικροσωματιδίων τα οποία προσκολλώνται στις επιφάνειες σωματιδίων που δρουν ως φορείς και τα οποία είναι ουσιαστικά πιο ευμεγέθη από τα σωματίδια του δραστικού παράγοντα, ή, παραγόντων, και είναι υδατοδιαλυτά, σε συνδυασμό με παράγοντα προαγωγής της βιοπροσκόλλησης και/ή της προσκόλλησης σε βλεννογόνο. Η εφεύρεση επίσης σχετίζεται με μέθοδο παρασκευής της σύνθεσης και με τη χρήση της σύνθεσης στην αγωγή έναντι αϋπνίας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9803240A SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | A pharmaceutical composition having a rapid action |
EP10001406.7A EP2236132B1 (en) | 1998-09-24 | 1999-09-24 | Pharmaceutical composition for the treatment of insomnia by sublingual administration |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115685T1 true CY1115685T1 (el) | 2017-01-25 |
Family
ID=20412702
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101054T CY1107711T1 (el) | 1998-09-24 | 2007-08-07 | Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων |
CY20131100974T CY1114620T1 (el) | 1998-09-24 | 2013-11-04 | Φαρμακευτικη συνθεση προς υπογλωσσια χορηγηση |
CY20141100588T CY1115685T1 (el) | 1998-09-24 | 2014-08-04 | Φαρμακευτικη συνθεση προς αγωγη εναντι αϋπνιας μεσω υπογλωσσιας χορηγησης |
CY20141100730T CY1115688T1 (el) | 1998-09-24 | 2014-09-10 | Φαρμακευτικη συνθεση που περιλαμβανει φεντανυλη προς αγωγη εναντι οξεος ή παροξυσμικου πονου μεσω υπογλωσσιας χορηγησης |
CY20171101261T CY1119644T1 (el) | 1998-09-24 | 2017-11-30 | Φαρμακευτικη συνθεση ταχειας δρασης που περιλαμβανει βουπρενορφινη |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101054T CY1107711T1 (el) | 1998-09-24 | 2007-08-07 | Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων |
CY20131100974T CY1114620T1 (el) | 1998-09-24 | 2013-11-04 | Φαρμακευτικη συνθεση προς υπογλωσσια χορηγηση |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100730T CY1115688T1 (el) | 1998-09-24 | 2014-09-10 | Φαρμακευτικη συνθεση που περιλαμβανει φεντανυλη προς αγωγη εναντι οξεος ή παροξυσμικου πονου μεσω υπογλωσσιας χορηγησης |
CY20171101261T CY1119644T1 (el) | 1998-09-24 | 2017-11-30 | Φαρμακευτικη συνθεση ταχειας δρασης που περιλαμβανει βουπρενορφινη |
Country Status (30)
Country | Link |
---|---|
US (8) | US6761910B1 (el) |
EP (5) | EP1652518B1 (el) |
JP (1) | JP3381220B2 (el) |
KR (1) | KR100760536B1 (el) |
CN (1) | CN1173694C (el) |
AT (1) | ATE365540T1 (el) |
AU (1) | AU764346B2 (el) |
BG (1) | BG65502B1 (el) |
BR (1) | BRPI9913945B8 (el) |
CA (3) | CA2629988C (el) |
CY (5) | CY1107711T1 (el) |
CZ (2) | CZ306387B6 (el) |
DE (1) | DE69936393T2 (el) |
DK (5) | DK1652518T3 (el) |
EE (3) | EE04927B1 (el) |
ES (5) | ES2644770T3 (el) |
HK (4) | HK1091722A1 (el) |
HU (2) | HU230342B1 (el) |
IL (1) | IL142135A0 (el) |
LU (1) | LU92636I2 (el) |
MX (1) | MXPA01003068A (el) |
NO (1) | NO332226B1 (el) |
NZ (1) | NZ510284A (el) |
PL (2) | PL201644B1 (el) |
PT (5) | PT2236133E (el) |
RU (1) | RU2193879C1 (el) |
SE (1) | SE9803240D0 (el) |
SK (1) | SK283302B6 (el) |
TR (1) | TR200100855T2 (el) |
WO (1) | WO2000016750A1 (el) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
SE9803239D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
SE9803240D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
UA77398C2 (en) | 2000-07-31 | 2006-12-15 | Nycomed Danmark As | Fentanyl composition for intranasal administration |
EP1341528B1 (en) * | 2000-12-07 | 2012-01-18 | Nycomed GmbH | Rapidly disintegrating tablet comprising an acid-labile active ingredient |
US20020106407A1 (en) * | 2000-12-11 | 2002-08-08 | Dennis Coleman | Method and apparatus for treating breakthrough pain |
JP4850346B2 (ja) * | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
US20030165566A1 (en) * | 2002-01-10 | 2003-09-04 | O'toole Edel | Sedative non-benzodiazepine formulations |
CA2472103A1 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
PT1487416E (pt) * | 2002-03-26 | 2010-01-25 | Teva Pharma | Micropartículas de fármacos |
ES2199061B1 (es) * | 2002-06-10 | 2005-02-16 | Laboratorios Vita, S.A. | Comprimidos bucodispersables y procedimiento para su obtencion. |
GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
CN101797221B (zh) | 2002-12-13 | 2013-06-12 | 杜雷科特公司 | 包含高粘度液体载体材料的口服递药系统 |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
PL211224B1 (pl) * | 2003-01-31 | 2012-04-30 | Orexo Ab | Kompozycja farmaceutyczna do leczenia ostrych zaburzeń przez podjęzykowe lub donosowe podawanie oraz jej zastosowanie |
ITRM20030288A1 (it) * | 2003-06-10 | 2004-12-11 | Valerio Cioli | Somministrazione sublinguale di antinfiammatori non steroidei (fans) |
WO2005039640A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan Inc. | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
EA010826B1 (ru) * | 2003-12-31 | 2008-12-30 | Сайма Лэбс Инк. | Лекарственная форма фентанила для перорального применения, способ ее получения и способы лечения |
JP5244318B2 (ja) | 2003-12-31 | 2013-07-24 | シーマ・ラブス、インコーポレイテッド | 発泡性経口アヘン薬投薬形態およびアヘン薬の投与方法 |
WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
US7658945B2 (en) * | 2004-02-17 | 2010-02-09 | Transcept Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US8163114B2 (en) * | 2004-04-07 | 2012-04-24 | New Jersey Institute Of Technology | Netshape manufacturing processes and compositions |
US20060127468A1 (en) * | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
HUE038247T2 (hu) * | 2004-05-19 | 2018-10-29 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Nátrium-deoxikolátot tartalmazó injektálható készítmény |
GB0423800D0 (en) * | 2004-10-27 | 2004-12-01 | Orexo Ab | New pharmaceutical formulations |
WO2006076552A2 (en) * | 2005-01-14 | 2006-07-20 | Cima Labs Inc. | Non-tearable child resistant blister package |
UA91843C2 (ru) * | 2005-01-14 | 2010-09-10 | Сайма Лебс Инк. | блистерная упаковка (варианты) и способ извлечения формы дозировки из нее |
CA2601969A1 (en) * | 2005-02-10 | 2006-08-17 | Orexo Ab | Pharmaceutical compositions useful in the transmucosal administration of drugs |
FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
US20090232898A1 (en) * | 2005-03-28 | 2009-09-17 | Anders Pettersson | Pharmaceutical Compositions Useful in the Treatment of Migraine |
NZ560826A (en) * | 2005-03-28 | 2009-06-26 | Orexo Ab | Composition comprising weak acid and particulate L-dopa useful in the treatment of parkinson's disease |
WO2006103418A1 (en) * | 2005-03-28 | 2006-10-05 | Orexo Ab | New pharmaceutical compositions useful in the treatment of pain |
US8242131B2 (en) * | 2005-05-25 | 2012-08-14 | Transcept Pharmaceuticals, Inc. | Methods of treating middle-of-the-night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
CN101198327B (zh) * | 2005-05-25 | 2012-06-20 | 特兰斯塞普特制药公司 | 治疗半夜失眠的固体组合物和方法 |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
EP2641595A1 (en) * | 2006-01-25 | 2013-09-25 | Insys Therapeutics, Inc. | Sublingual fentanyl spray |
BRPI0709872A2 (pt) * | 2006-04-03 | 2011-07-26 | Teva Pharma | micropartÍculas de drogas |
US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
EP2037895A4 (en) * | 2006-05-23 | 2009-12-02 | Orahealth Corp | XYLITOL-PASTILLAS AND METHOD OF USE |
US20070286900A1 (en) * | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
ITMI20061117A1 (it) * | 2006-06-09 | 2007-12-10 | Michele Bonanomi | Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
PT2101740E (pt) | 2006-12-04 | 2013-12-23 | Orexo Ab | Nova composição farmacêutica não susceptível de abuso que compreende opióides |
WO2008070795A2 (en) * | 2006-12-06 | 2008-06-12 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
CA2673481A1 (en) | 2006-12-19 | 2008-06-26 | University Of Virginia Patent Foundation | Combined effects of topiramate and ondansetron on alcohol consumption |
DE102007010109A1 (de) * | 2007-02-28 | 2008-09-04 | Henkel Ag & Co. Kgaa | Wirkstoffträgersysteme |
CA2959274C (en) * | 2007-12-06 | 2019-07-09 | Pain Therapeutics, Inc. | Micronized opioid compositions, formulations and dosage forms and methods of making same |
AU2008347158B8 (en) | 2007-12-06 | 2013-08-22 | Durect Corporation | Oral pharmaceutical dosage forms |
WO2009098169A1 (en) * | 2008-02-05 | 2009-08-13 | Alpex Pharma Sa | Orally disintegrating tablets with speckled appearance |
US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
EP2111857A1 (de) * | 2008-04-25 | 2009-10-28 | Acino AG | Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
SE533540C2 (sv) | 2008-12-19 | 2010-10-19 | Neoinvent Medical Engineering Ab | Administrerinssystem för administrering av en substans i munhålan |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
JP5702526B2 (ja) | 2009-04-30 | 2015-04-15 | Esファイバービジョンズ株式会社 | 抗ウイルス性を有する硫酸化セルロースを担持させた繊維集合体 |
AU2010300641B2 (en) | 2009-09-30 | 2016-03-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
PL2493457T3 (pl) | 2009-10-30 | 2018-01-31 | Ix Biopharma Ltd | Szybko rozpuszczalna stała postać dawkowana |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2519229A2 (en) | 2009-12-29 | 2012-11-07 | Novartis AG | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2801625B1 (en) | 2010-07-02 | 2017-11-01 | University Of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
ITMI20101426A1 (it) * | 2010-07-29 | 2012-01-30 | Altergon Sa | Composizione contenente condroitin solfato |
FR2967066B1 (fr) * | 2010-11-04 | 2013-06-14 | Ethypharm Sa | Utilisation par voie sublinguale de microgranules non comprimes |
WO2012106058A2 (en) * | 2011-01-31 | 2012-08-09 | New Market Pharmaceuticals | Animal treatments |
MX363465B (es) | 2011-02-18 | 2019-03-25 | Kythera Biopharmaceuticals Inc | Tratamiento de la grasa submental. |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
MX2013013104A (es) | 2011-05-09 | 2014-10-15 | Univ Virginia Patent Found | Composiciones y metodos para el tratamiento de cancer. |
EA027743B1 (ru) | 2011-09-09 | 2017-08-31 | Юниверсити Оф Вирджиния Пэтент Фаундейшн | Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости |
DK2706986T3 (en) | 2011-09-19 | 2015-06-01 | Orexo Ab | NEW ADDICTION PREVENTING PHARMACEUTICAL COMPOSITION FOR TREATMENT OF OPIOID ADDICTION |
SI3150199T1 (sl) | 2012-05-02 | 2018-12-31 | Orexo Ab | Novi sestavek alfentanila za zdravljenje akutne bolečine |
WO2014085599A1 (en) | 2012-11-30 | 2014-06-05 | Acura Pharmaceuticals, Inc. | Self-regulated release of active pharmaceutical ingredient |
WO2014144975A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
MX2016006087A (es) | 2013-11-11 | 2016-08-12 | Impax Laboratories Inc | Formulaciones de desintegracion rapida y metodos de uso. |
US10617686B2 (en) | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
US9642848B2 (en) | 2014-07-08 | 2017-05-09 | Insys Development Company, Inc. | Sublingual naloxone spray |
US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
AU2015369710B2 (en) | 2014-12-23 | 2020-09-17 | Vertical Pharmaceuticals, Llc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
US20170119660A1 (en) * | 2015-10-29 | 2017-05-04 | Solubest Ltd | Pharmaceutical compositions for transmucosal delivery |
WO2017177037A1 (en) | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
CN107157994A (zh) * | 2017-06-09 | 2017-09-15 | 董鹏 | 一种托拉塞米的舌下口服制剂 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4206209A (en) * | 1978-11-02 | 1980-06-03 | Kracauer Paul | Sublingual aspirin tablet |
US4229447A (en) * | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4432975A (en) * | 1981-04-13 | 1984-02-21 | Icn Pharmaceuticals, Inc. | Process for introducing vitamin B-12 into the bloodstream |
DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
GB8522453D0 (en) * | 1985-09-11 | 1985-10-16 | Lilly Industries Ltd | Chewable capsules |
DE3715682A1 (de) * | 1987-05-11 | 1988-11-24 | Stefan Dr Lueth | Vorrichtung zum herstellen eines zweikomponentengemisches |
SE8800080L (sv) | 1988-01-13 | 1989-07-14 | Kabivitrum Ab | Laekemedelskomposition |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4866046A (en) * | 1988-05-31 | 1989-09-12 | Top Laboratories, Inc. | Low-dosage sublingual aspirin |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
SE8803935L (sv) * | 1988-10-31 | 1990-05-01 | Kabivitrum Ab | Laekemedelskomposition |
US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
DE69009946T2 (de) * | 1989-12-04 | 1994-11-03 | Searle & Co | System zur transdermalen Albuterol Applikation. |
US5370862A (en) * | 1990-06-13 | 1994-12-06 | Schwarz Pharma Ag | Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina |
FR2694194B1 (fr) | 1992-07-31 | 1994-11-04 | Health Business Dev | Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel. |
JPH0665103A (ja) | 1992-08-13 | 1994-03-08 | ▲寛▼治 ▲高▼田 | 向精神薬のための速吸収性舌下投与製剤 |
WO1994006426A1 (en) | 1992-09-21 | 1994-03-31 | Qin Bo Yi | Methods for identifying and using low/non-addictive opioid analgesics |
DE69429119T2 (de) | 1993-07-09 | 2002-07-18 | R.P. Scherer Corp., Troy | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen |
GB9401894D0 (en) * | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
US5948389A (en) * | 1995-06-07 | 1999-09-07 | El Khoury & Stein, Ltd. | Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics |
US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
US5733571A (en) * | 1995-12-08 | 1998-03-31 | Euro-Celtique, S.A. | Transdermal patch for comparative evaluations |
US5762961A (en) * | 1996-02-09 | 1998-06-09 | Quadrant Holdings Cambridge Ltd. | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof |
US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
DE19652188C2 (de) | 1996-12-16 | 2002-02-14 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung |
DE19652268C2 (de) | 1996-12-16 | 2000-06-29 | Lohmann Therapie Syst Lts | Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19758564A1 (de) * | 1997-11-11 | 1999-08-26 | Gruenenthal Gmbh | Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung |
KR100289471B1 (ko) * | 1998-01-19 | 2001-09-17 | 김충섭 | 휀타닐계마취제의이식형서방성제제 |
US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US6264974B1 (en) * | 1998-07-07 | 2001-07-24 | Salvagnini Italia Spa | Buccal and sublingual administration of physostigmine |
SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
SE9803239D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
EP1005863A1 (en) | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
AU7937500A (en) | 1999-10-27 | 2001-05-08 | Farmarc Nederland Bv | Pharmaceutical composition containing midazolam |
WO2001078725A2 (en) * | 2000-04-13 | 2001-10-25 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
CN1290525A (zh) | 2000-10-10 | 2001-04-11 | 北京万全阳光医药科技有限公司 | 冷冻干燥的扎来普隆速溶口服组合物 |
US20030035839A1 (en) | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
DE60319802T2 (de) | 2002-01-10 | 2008-07-10 | Biovail Laboratories International S.R.L. | Sedierende nicht-benzodiazepin-formulierungen |
CN1418631A (zh) | 2002-12-19 | 2003-05-21 | 王登之 | 治疗失眠的佐匹克隆口腔崩解片及其制备方法 |
US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
-
1998
- 1998-09-24 SE SE9803240A patent/SE9803240D0/xx unknown
-
1999
- 1999-09-24 PT PT100014083T patent/PT2236133E/pt unknown
- 1999-09-24 EE EEP200100182A patent/EE04927B1/xx unknown
- 1999-09-24 PL PL347126A patent/PL201644B1/pl unknown
- 1999-09-24 PT PT141750851T patent/PT2805716T/pt unknown
- 1999-09-24 ES ES14175085.1T patent/ES2644770T3/es not_active Expired - Lifetime
- 1999-09-24 TR TR2001/00855T patent/TR200100855T2/xx unknown
- 1999-09-24 NZ NZ510284A patent/NZ510284A/en not_active IP Right Cessation
- 1999-09-24 DE DE69936393T patent/DE69936393T2/de not_active Expired - Lifetime
- 1999-09-24 IL IL14213599A patent/IL142135A0/xx not_active IP Right Cessation
- 1999-09-24 MX MXPA01003068A patent/MXPA01003068A/es active IP Right Grant
- 1999-09-24 EE EEP200800028A patent/EE05555B1/xx unknown
- 1999-09-24 WO PCT/SE1999/001687 patent/WO2000016750A1/en active Application Filing
- 1999-09-24 DK DK05077875.2T patent/DK1652518T3/da active
- 1999-09-24 DK DK10001408.3T patent/DK2236133T3/da active
- 1999-09-24 SK SK402-2001A patent/SK283302B6/sk not_active IP Right Cessation
- 1999-09-24 CZ CZ2008-315A patent/CZ306387B6/cs not_active IP Right Cessation
- 1999-09-24 DK DK14175085.1T patent/DK2805716T3/en active
- 1999-09-24 HU HU0103856A patent/HU230342B1/hu unknown
- 1999-09-24 CA CA2629988A patent/CA2629988C/en not_active Expired - Lifetime
- 1999-09-24 ES ES05077875T patent/ES2433930T3/es not_active Expired - Lifetime
- 1999-09-24 EP EP05077875.2A patent/EP1652518B1/en not_active Expired - Lifetime
- 1999-09-24 AU AU64927/99A patent/AU764346B2/en active Active
- 1999-09-24 HU HU0800435A patent/HU230468B1/hu unknown
- 1999-09-24 DK DK99952867T patent/DK1115383T3/da active
- 1999-09-24 CZ CZ20011029A patent/CZ302975B6/cs not_active IP Right Cessation
- 1999-09-24 US US09/787,888 patent/US6761910B1/en not_active Expired - Lifetime
- 1999-09-24 KR KR1020017003715A patent/KR100760536B1/ko active IP Right Grant
- 1999-09-24 RU RU2001111025/14A patent/RU2193879C1/ru active
- 1999-09-24 EP EP10001408.3A patent/EP2236133B1/en not_active Expired - Lifetime
- 1999-09-24 PT PT99952867T patent/PT1115383E/pt unknown
- 1999-09-24 JP JP2000573711A patent/JP3381220B2/ja not_active Expired - Lifetime
- 1999-09-24 CA CA2820588A patent/CA2820588C/en not_active Expired - Lifetime
- 1999-09-24 EP EP14175085.1A patent/EP2805716B1/en not_active Revoked
- 1999-09-24 PL PL383971A patent/PL204264B1/pl unknown
- 1999-09-24 DK DK10001406.7T patent/DK2236132T3/da active
- 1999-09-24 PT PT100014067T patent/PT2236132E/pt unknown
- 1999-09-24 EP EP10001406.7A patent/EP2236132B1/en not_active Expired - Lifetime
- 1999-09-24 PT PT50778752T patent/PT1652518E/pt unknown
- 1999-09-24 BR BRPI9913945A patent/BRPI9913945B8/pt not_active IP Right Cessation
- 1999-09-24 EP EP99952867A patent/EP1115383B1/en not_active Expired - Lifetime
- 1999-09-24 ES ES99952867T patent/ES2289829T3/es not_active Expired - Lifetime
- 1999-09-24 EE EEP200700030A patent/EE05023B1/xx unknown
- 1999-09-24 CA CA002345121A patent/CA2345121C/en not_active Expired - Lifetime
- 1999-09-24 CN CNB998135453A patent/CN1173694C/zh not_active Expired - Lifetime
- 1999-09-24 AT AT99952867T patent/ATE365540T1/de active
- 1999-09-24 ES ES10001408.3T patent/ES2498095T3/es not_active Expired - Lifetime
- 1999-09-24 ES ES10001406.7T patent/ES2507579T3/es not_active Expired - Lifetime
-
2001
- 2001-03-22 NO NO20011473A patent/NO332226B1/no not_active IP Right Cessation
- 2001-03-23 BG BG105379A patent/BG65502B1/bg unknown
-
2004
- 2004-05-24 US US10/851,215 patent/US20040213855A1/en not_active Abandoned
-
2006
- 2006-10-10 US US11/544,660 patent/US7910132B2/en not_active Expired - Fee Related
- 2006-10-25 HK HK06111773.4A patent/HK1091722A1/xx not_active IP Right Cessation
- 2006-10-25 HK HK11102568.5A patent/HK1148458A1/xx not_active IP Right Cessation
- 2006-10-25 HK HK11102567.6A patent/HK1148457A1/xx not_active IP Right Cessation
-
2007
- 2007-08-07 CY CY20071101054T patent/CY1107711T1/el unknown
-
2008
- 2008-07-01 US US12/216,197 patent/US20080286368A1/en not_active Abandoned
-
2011
- 2011-11-22 US US13/302,694 patent/US8454996B2/en not_active Expired - Fee Related
- 2011-11-22 US US13/302,720 patent/US8512747B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 US US13/799,640 patent/US20130195976A1/en not_active Abandoned
- 2013-07-30 US US13/954,141 patent/US20140030336A1/en not_active Abandoned
- 2013-11-04 CY CY20131100974T patent/CY1114620T1/el unknown
-
2014
- 2014-08-04 CY CY20141100588T patent/CY1115685T1/el unknown
- 2014-09-10 CY CY20141100730T patent/CY1115688T1/el unknown
-
2015
- 2015-01-20 LU LU92636C patent/LU92636I2/xx unknown
- 2015-04-14 HK HK15103632.1A patent/HK1203144A1/xx not_active IP Right Cessation
-
2017
- 2017-11-30 CY CY20171101261T patent/CY1119644T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115685T1 (el) | Φαρμακευτικη συνθεση προς αγωγη εναντι αϋπνιας μεσω υπογλωσσιας χορηγησης | |
CY1106154T1 (el) | Ταχεως-δρωσα φαρμακευτικη συνθεση | |
SE9803239D0 (sv) | Composition for the treatment of acute pain | |
CY1105931T1 (el) | Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας | |
PT954314E (pt) | Formas de dosagem farmaceutica para melhorar a disfuncao erectil masculina | |
HUP9902076A2 (hu) | Szexuális rendellenességek kezelésére alkalmas intranazális készítmény | |
BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
EA200400007A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
DE602004009552D1 (de) | Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel | |
BR0007452A (pt) | Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação | |
HUP0203050A2 (hu) | Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények | |
ES2188513T3 (es) | Utilizacion de desoxipeganina para el tratamiento de la drogodependencia. | |
MXPA02006034A (es) | Formas de dosis mucosaloral de apomorfina. | |
CY1105347T1 (el) | Η χρηση της προπιονυλο l-καρνιτινης ή ενος απο τα φαρμακολογικα αποδεκτα αλατα της για την παρασκευη ενος φαρμακου για τη θepαπευτικη αντιμετωπιση της νοσου του peyronie | |
UA29558C2 (uk) | Препарат для лікування бронхіальної астми " еуфілін-н 200" | |
WO2001035946A3 (en) | Intranasal administration of raloxifene and tamoxifen | |
BR9810930A (pt) | Composições farmacêuticas de arglabina e derivados de arglabina |